Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.
about
Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcomaProgression of cutaneous melanoma: implications for treatmentTriterpenoids amplify anti-tumoral effects of mistletoe extracts on murine B16.f10 melanoma in vivoCopper is required for oncogenic BRAF signalling and tumorigenesisTargeted inhibition of BRAF kinase: opportunities and challenges for therapeutics in melanoma.Resistance to chemotherapy and molecularly targeted therapies: rationale for combination therapy in malignant melanomaA phase I multi-institutional study of systemic sorafenib in conjunction with regional melphalan for in-transit melanoma of the extremity.In vivo profiling reveals immunomodulatory effects of sorafenib and dacarbazine on melanoma.Resveratrol and clofarabine induces a preferential apoptosis-activating effect on malignant mesothelioma cells by Mcl-1 down-regulation and caspase-3 activation.Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3β and NF-κB to suppress tumor cell growthClusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model.Genetics of melanomaBevacizumab-induced alterations in vascular permeability and drug delivery: a novel approach to augment regional chemotherapy for in-transit melanoma.Flavopiridol synergizes with sorafenib to induce cytotoxicity and potentiate antitumorigenic activity in EGFR/HER-2 and mutant RAS/RAF breast cancer model systems.The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cellsSRC family kinase inhibition as a novel strategy to augment melphalan-based regional chemotherapy of advanced extremity melanoma.Regional treatment strategies for in-transit melanoma metastasis.Minimally invasive intra-arterial regional therapy for metastatic melanoma: isolated limb infusion and percutaneous hepatic perfusion.Towards new therapeutic approaches for malignant melanoma.Isolated limb infusion as a model to test new agents to treat metastatic melanoma.The current management of brain metastasis in melanoma: a focus on riluzole.Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of ImmunotherapyTargeting N-cadherin increases vascular permeability and differentially activates AKT in melanoma.Potential therapeutic targets of epithelial-mesenchymal transition in melanoma.Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies.Constitutive ERK activity induces downregulation of tristetraprolin, a major protein controlling interleukin8/CXCL8 mRNA stability in melanoma cells.Copper Chelation Inhibits BRAFV600E-Driven Melanomagenesis and Counters Resistance to BRAFV600E and MEK1/2 Inhibitors.Molecular Dynamics Simulation of VEGFR2 with Sorafenib and Other Urea-Substituted Aryloxy Compounds
P2860
Q26747666-2C0BD04C-5CF7-4E25-8DF8-6C87F06C7226Q27001734-F63AADA4-9048-400D-96C3-939BD57EAD02Q27323005-F8F6A6CB-AB52-4A39-BFCE-CB7A73872DD4Q28237892-8B9F04DB-68F3-43BF-B376-40D4D8F283C9Q34222257-0DBF1417-B8AE-401D-99FB-6C18E8429FF7Q34497045-95B27CEB-CD11-436F-B7DC-3AAE583B22F4Q35471445-B4424E85-2701-4B04-8790-084657A802B6Q35506764-0634A39F-BA8C-4D74-A3E6-B8402F120E95Q35676344-82317C9E-063D-43FA-8631-841485D713B7Q35928707-8D4AF814-9CC6-4B9B-9B66-2FB349F021FAQ36072803-30BD67D8-FDEC-45CF-A392-453B7D6B54F3Q36563659-9F70F12F-3FF7-4201-93E2-2F42CB2A2DAAQ36744566-CC880DCD-B094-4EC2-908D-AE5B03B6D4A7Q37061029-065F2B57-5C91-43C3-9346-6668509FA600Q37308167-C15E1665-E15A-44FB-92A8-E942EABFB02CQ37509699-C0539F0C-6498-492F-928E-1D29CB8DD0F2Q37812815-0BD1D1D9-26B5-4310-8DD8-6D3DBED032A8Q37943015-10DA262B-8B41-4A80-88F1-D8217834F65AQ37951743-62F59B70-285B-4573-9934-EFEA914ACDB9Q38187595-384A6A9D-8136-4CAB-82B8-8667F912AB54Q38532696-E20DE4AD-17C2-4CED-B786-DBBEA78E68FAQ38867762-852B9F8A-26A8-44AB-B0A1-F6A81A3E3265Q39013913-E2735E95-6F58-4F15-BF4A-FE19597F1C85Q39107981-52609662-0951-48B8-B624-1AD6653D48B8Q39168954-D2FB24FE-826D-4543-AB76-540E9E1A730DQ39540154-CE3A0017-CCCE-4F28-9DCC-29A01BD58BC7Q47684992-6EDC487D-C411-4B77-B68D-FDBECDDA1948Q59022306-11F9F799-2629-4F6D-8096-0214451B29E0
P2860
Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Sorafenib, a multikinase inhib ...... noma to regional chemotherapy.
@en
Sorafenib, a multikinase inhib ...... noma to regional chemotherapy.
@nl
type
label
Sorafenib, a multikinase inhib ...... noma to regional chemotherapy.
@en
Sorafenib, a multikinase inhib ...... noma to regional chemotherapy.
@nl
prefLabel
Sorafenib, a multikinase inhib ...... noma to regional chemotherapy.
@en
Sorafenib, a multikinase inhib ...... noma to regional chemotherapy.
@nl
P2093
P1476
Sorafenib, a multikinase inhib ...... noma to regional chemotherapy.
@en
P2093
Christina K Augustine
Douglas S Tyler
Francis Ali-Osman
Hiroaki Toshimitsu
James Burchette
James Padussis
M Angelica Selim
Nicole McMahon
Patricia A Zipfel
P304
P356
10.1158/1535-7163.MCT-10-0073
P577
2010-06-22T00:00:00Z